AP Biosciences Inc.

6945 · TPEx · Taiwan

Public Market Listing

6945TPEx

TPEx primary exchange listing

Live quotes, historical charts, and market capitalization for AP Biosciences Inc. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Phase 2
PD-L1 / VEGFMultispecific antibody
Non-Small Cell Lung Cancer
Phase 1/2
PD-L1 + 4-1BB (CD137)Multispecific antibody
Non-Small Cell Lung Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
AP203Phase 1/2Locally Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) …
Est. primary completion 2026-12 · NCT05473156 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.